Eculizumab

• UNSPSC Description:

  Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research[1].

• Target Antigen:

  Complement System

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Immunology/Inflammation

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/eculizumab.html

• Purity:

  97.81

• Solubility:

  H2O

• Smiles:

  [Eculizumab]

• References & Citations:

  [1]Eline A Dubois,et al. Eculizumab. Br J Clin Pharmacol. 2009 Sep;68(3):318-9.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Clinical Information:

  Launched

• CAS Number:

  219685-50-4